UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

Diabetes, obesity & metabolism, 2013-09, Vol.15 (9), p.853-862

2013

Volltextzugriff (PDF)

A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus

Diabetologia, 2013-02, Vol.56 (2), p.259-267

2013

Volltextzugriff (PDF)

Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus

Diabetic medicine, 2014-09, Vol.31 (9), p.1138-1147

2014

Volltextzugriff (PDF)

Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial

PloS one, 2017-01, Vol.12 (1), p.e0169258-e0169258

2017

Volltextzugriff (PDF)

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Diabetologia, 2011-01, Vol.54 (1), p.44-50

2011

Volltextzugriff (PDF)

Quantitative aortic Na[ 18 F]F positron emission tomography computed tomography as a tool to associate vascular calcification with major adverse cardiovascular events

European journal of nuclear medicine and molecular imaging, 2024-09

2024

Volltextzugriff (PDF)

Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2016-01, Vol.18 (1), p.64-71

2016

Volltextzugriff (PDF)

Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review

Diabetic medicine, 2015-07, Vol.32 (7), p.853-864

2015

Volltextzugriff (PDF)

Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes

Diabetes & vascular disease research, 2018-01, Vol.15 (1), p.14-23

2018

Volltextzugriff (PDF)

Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review

Diabetic medicine, 2012-05, Vol.29 (5), p.567-577

2012

Volltextzugriff (PDF)

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

European journal of preventive cardiology, 2014-04, Vol.21 (4), p.434-441

2014

Volltextzugriff (PDF)

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

Journal of pharmacokinetics and pharmacodynamics, 2014-12, Vol.41 (6), p.545-552

2014

Volltextzugriff (PDF)

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]

Diabetologia, 2011-11, Vol.54 (11), p.2965-2967

2011

Volltextzugriff (PDF)

Development of a radioiodinated apoptosis–inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies

British journal of pharmacology, 2012-04, Vol.165 (7), p.2203-2212

2012

Volltextzugriff (PDF)

Dual RAS Therapy Not on Target, but Fully Alive

Nephron, 2010-09, Vol.116 (2), p.c137-c142

2010

Volltextzugriff (PDF)

Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus

Diabetic medicine, 2009-05, Vol.26 (5), p.556-559

2009

Volltextzugriff (PDF)

Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy

Diabetic medicine, 2007-11, Vol.24 (11), p.1290-1295

2007

Volltextzugriff (PDF)

Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials?

Nephron, 2011-10, Vol.119 (3), p.c195-c199

2011

Volltextzugriff (PDF)

Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. ‘Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes’

Diabetologia, 2015-12, Vol.58 (12), p.2901-2901

2015

Volltextzugriff (PDF)

POS-380 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (THE ALIGN STUDY)

Kidney international reports, 2021-04, Vol.6 (4), p.S164-S165

2021

Volltextzugriff (PDF)

CA-048: La dapagliflozine réduit l'albuminurie en plus d'inhiber le système rénine – angiotensine chez les patients DT2 hypertendus

Diabetes & metabolism, 2016-03, Vol.42, p.A48-A48

2016

Volltextzugriff (PDF)

POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL

Kidney international reports, 2021-04, Vol.6 (4), p.S362-S362

2021

Volltextzugriff (PDF)

POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL

Kidney international reports, 2021-04, Vol.6 (4), p.S361-S362

2021

Volltextzugriff (PDF)

The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers

Clinical pharmacology and therapeutics, 2014-02, Vol.95 (2), p.208-215

2014

Volltextzugriff (PDF)

Inhibition of the Renin-Angiotensin-Aldosterone System for Cerebrorenal Protection

Contributions to nephrology, 2013, Vol.179, p.7-14

2013

Volltextzugriff (PDF)

1 – 25 von 110

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus

Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus

Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Quantitative aortic Na[ 18 F]F positron emission tomography computed tomography as a tool to associate vascular calcification with major adverse cardiovascular events

Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes

Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review

Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes

Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]

Development of a radioiodinated apoptosis–inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies

Dual RAS Therapy Not on Target, but Fully Alive

Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus

Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy

Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials?

Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. ‘Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes’

POS-380 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (THE ALIGN STUDY)

CA-048: La dapagliflozine réduit l'albuminurie en plus d'inhiber le système rénine – angiotensine chez les patients DT2 hypertendus

POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL

POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL

The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers

Inhibition of the Renin-Angiotensin-Aldosterone System for Cerebrorenal Protection

Suchergebnisse filtern